The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Biosimilars in Oncology

Highly similar copies of biologics with comparable efficacy and lower cost

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Biosimilars in Oncology?

Biosimilars are biologic products developed to be highly similar to a previously approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. They are not generic copies — biologics are large complex molecules produced in living cells and cannot be exactly duplicated — but extensive comparability testing ensures equivalence within accepted ranges.

Approval requires a stepwise comparability exercise: structural and functional analytical studies, animal pharmacology and toxicology, comparative pharmacokinetic and pharmacodynamic studies, and a confirmatory clinical study in a sensitive indication. Once approved, regulatory extrapolation may extend approval to other indications of the reference product based on the totality of evidence.

In oncology biosimilars are available for trastuzumab, bevacizumab, rituximab, and supportive care biologics including filgrastim, pegfilgrastim, and epoetin. Studies show comparable efficacy and safety with significant cost savings, increasing access to therapy. Patients can typically be switched between reference and biosimilar within a treatment course according to local policy.

Symptoms

Treatment continues to control disease as expected
Side effects similar to reference biologic
Infusion reactions remain uncommon
Disease response on imaging remains comparable

Risk Factors

Cost barriers limiting access to reference biologic
Indications where reference biologic is standard of care
Established patient on long-term reference biologic
Need for supportive care biologics across treatment cycles

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Decision about starting a new biologic for cancer or supportive care
  • Discussion of switching from reference to biosimilar
  • Concerns about new infusion reactions or efficacy after a switch
  • Need to access expensive biologic with cost barriers

Treatment Methods

01
Initiate biosimilar where supported by guidelines and policy
02
Switch from reference biologic per institutional protocols
03
Monitor disease response and adverse events as for reference
04
Pharmacovigilance and lot-specific tracking to support safety
05
Patient education on biosimilar concept and equivalence
06
Cost-savings discussion as part of shared decision making
07
Multidisciplinary input from oncology and pharmacy

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.